1.
Baseline profiles, treatment effects and complications (N=187)
| Factors | n (%) | χ2 | P | ||
| Group A | Group B | Group C | |||
| Total number | 62 | 58 | 67 | ||
| Baseline profiles | |||||
| Age (year) | |||||
| <46 | 30 (48.4) | 31 (53.4) | 26 (38.8) | 2.808 | 0.246 |
| ≥46 | 32 (51.6) | 27 (46.6) | 41 (61.2) | ||
| Gender | |||||
| Male | 50 (80.6) | 44 (75.9) | 45 (67.2) | 3.170 | 0.205 |
| Female | 12 (19.4) | 14 (24.1) | 22 (32.8) | ||
| Stage | |||||
| I–II | 20 (32.3) | 16 (27.6) | 15 (22.4) | 1.586 | 0.453 |
| III–IVB | 42 (67.7) | 42 (72.4) | 52 (77.6) | ||
| RT toxicities | |||||
| Mucositis | |||||
| No | 2 (3.2) | 3 (5.2) | 14 (20.9) | 13.306 | 0.001 |
| Yes | 60 (96.8) | 55 (94.8) | 53 (79.1) | ||
| Xerostomia | |||||
| No | 8 (12.9) | 6 (10.3) | 9 (13.4) | 0.306 | 0.858 |
| Yes | 54 (87.1) | 52 (89.7) | 58 (86.6) | ||
| Myelosuppression | |||||
| No | 21 (33.9) | 17 (29.3) | 24 (35.8) | 0.616 | 0.735 |
| Yes | 41 (66.1) | 41 (70.7) | 43 (64.2) | ||
| Grade 3/4 mucositis | |||||
| No | 47 (75.8) | 40 (69.0) | 44 (65.7) | 1.624 | 0.444 |
| Yes | 15 (24.2) | 18 (31.0) | 23 (34.3) | ||
| Grade 3/4 xerostomia | |||||
| No | 57 (91.9) | 56 (96.6) | 63 (94.0) | 1.155 | 0.561 |
| Yes | 5 (8.1) | 2 (3.4) | 4 (6.0) | ||
| Grade 3/4 myelosuppression | |||||
| No | 59 (95.2) | 55 (94.8) | 63 (94.0) | 0.087 | 0.958 |
| Yes | 3 (4.8) | 3 (5.2) | 4 (6.0) | ||
| Treatment effects | |||||
| CR rate at 30 fractions | |||||
| No | 20 (32.3) | 12 (20.7) | 15 (22.4) | 2.550 | 0.279 |
| Yes | 42 (67.7) | 46 (79.3) | 52 (76.6) | ||
| CR rate at 3 months | |||||
| No | 8 (12.9) | 7 (12.1) | 9 (13.4) | 0.052 | 0.974 |
| Yes | 54 (87.1) | 51 (87.9) | 58 (86.6) | ||
| AMF complications | |||||
| GI reaction | |||||
| No | 23 (37.1) | 15 (25.9) | 18 (26.9) | 2.275 | 0.321 |
| Yes | 39 (62.9) | 43 (74.1) | 49 (73.1) | ||
| Table 1 (continued) | |||||